Deep Track Capital portfolio
Investment firmPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Deep Track Capital reported a $6.8 bn portfolio of 66 positions to the SEC as of the end of Q2 2026. Its largest positions are GH, IMVT, GPCR. During the quarter it opened Alnylam Pharmaceuticals and GH Research and exited BridgeBio Pharma.
Sections with a free account
What it reported after the quarter end (Q2 2026)
The 13F shows the portfolio as of Jun 30, 2026. Since then Deep Track Capital has filed these own trades with the SEC (Form 4, when it owns more than 10% of a company or holds a role in it) and stakes above 5% (13D and 13G). It is not everything it did: only what it must report before the next 13F.
Stake reported in the company · event of Oct 16, 2026 · filed Oct 23, 2026 · filing ↗
- 13GJatt III Acquisition5.8 %
Stake reported in the company · event of Aug 26, 2026 · filed Sep 2, 2026 · filing ↗
- 13GLatigo Biotherapeutics7 %
Stake reported in the company · event of Aug 7, 2026 · filed Aug 13, 2026 · filing ↗
- 13GAttovia Therapeutics7.5 %
Stake reported in the company · event of Aug 5, 2026 · filed Aug 12, 2026 · filing ↗
- 13GObsidian Therapeutics5.4 %
Stake reported in the company · event of Aug 4, 2026 · filed Aug 11, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Plus 7 more, in its EDGAR filings.
What changed this quarter
59 positions with a change (15 new, 20 added to, 14 trimmed, 10 sold); also, 2 entered through an IPO, 4 exited through an acquisition or merger, 1 entered through a spin-off. 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Alnylam Pharmaceuticals+3.7 ppof portfolioNew— → 3.7%
- Veradermics+300%more sharesIncreased0.7% → 3.6%
- BioMarin Pharmaceutical+188%more sharesIncreased1.3% → 2.8%
- Axsome Therapeutics−36%fewer sharesReduced3.8% → 2.5%
- GH Research+1.3 ppof portfolioNew— → 1.3%
- Immunovant−19%fewer sharesReduced5.9% → 5.3%
- United Therapeutics+1.0 ppof portfolioNew— → 1.0%
- Avalo Therapeutics+1.0 ppof portfolioNew— → 1.0%
- BridgeBio Pharma−0.9 ppof portfolioSold out1.3% → —
- Celldex Therapeutics+129%more sharesIncreased0.8% → 1.6%
- Altimmune+0.9 ppof portfolioNew— → 0.9%
- Cytokinetics−49%fewer sharesReduced1.9% → 0.9%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Guardant HealthGH7.5%
- ImmunovantIMVT5.3%
- Structure TherapeuticsGPCR3.7%
- VaxcytePCVX3.7%
- Alnylam PharmaceuticalsALNY3.7%
- VeradermicsMANE3.6%
- Tarsus PharmaceuticalsTARS3.4%
- Nuvalent3.2%
- Alkermes plc.ALKS3.1%
- Ocular TherapeutixOCUL2.8%
- BioMarin PharmaceuticalBMRN2.8%
- Nurix TherapeuticsNRIX2.8%
- Oruka TherapeuticsORKA2.7%
- AlumisALMS2.6%
- Ionis PharmaceuticalsIONS2.6%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 100%
How its portfolio changed (8 quarters)
Q2 2026: 66
Q2 2026: 40%
Q2 2026: 16.6%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Declared options (1)
Besides stocks, Deep Track Capital declared 1 call (they gain if it rises) with a notional of $82.4M. The 13F reports the value of the underlying shares, not the premium paid, so these figures look large and are not added to the portfolio. Nor does it say whether the option is bought or written, or its strike or expiry: it may be a hedge.
- CALLGenmab A/SGMABnew this quarter$82.4M
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Investment firm, per its Form ADV of Mar 31, 2026 (high confidence).
The data, as reported: DEEP TRACK CAPITAL, LP (CRD 312459): 7.B private funds: 2 hedge (gross assets $8.4 bn); 5.D assets by client type: pooled vehicles 100% (of $8.4 bn)
The type comes from a rule applied to that data. If it looks wrong, tell us.
Not counted as a concentrated manager: its top 10 positions are under 45%. Its portfolio is shown all the same, but it is left out of manager counts, the consensus and the ranking. How this is decided
Similar managers by type and size
Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.
- Reaves W HInvestment firm · $6.6 bn
- Ruane, Cunniff & GoldfarbInvestment firm · $6.4 bn
- Slate Path CapitalInvestment firm · $7.2 bn
- ACR Alpine Capital ResearchInvestment firm · $7.4 bn
- Alpha Wave GlobalInvestment firm · $6.2 bn
- AppaloosaInvestment firm · $7.5 bn